XOMA Corp (XOMA) Well Above-Consensus; CYREN (CYRN) Insiders See Opportunity


Shares of XOMA Corp. (Nasdaq:XOMA) soared more than 20% in after-hours trading Wednesday as  the company delivered quarterly financial results well above Wall Street analysts’ expectations, driven by its licensing activity during the period.

For the fourth quarter 2015, XOMA posted revenues of $48.2 million and net income of $25.4 million or $0.21 per diluted share, easily surpassing the Capital IQ Consensus estimate of ($0.13) loss per share on revenues of $2.25 million for the period. The company said that it has initiated a formal sales process for gevokizumab.

XOMA stock closed at $0.888, up 0.008 (or +0.89%), with a total volume of 2,447,003 shares traded during the regular session

XOMA Corp., a leader in the discovery and development of therapeutic antibodies, has 118.82M Shares Outstanding, Market Capitalization (intraday) of $105.48M and XOMA stock 52-week range is between $0.69 and $4.93 per share



The price of CYREN Ltd. (Nasdaq:CYRN) stock surged in pre-market trade Thursday after the company said that several of its executives – including CEO and CFO – bought more than 170,000 shares of CYREN during the past quarter in the open market

CYRN stock closed at $1.59, down $0.03 (or -1.85%)  on Wednesday’s trading session

CYREN, which provides Internet security solutions, has 39.09M Shares Outstanding, Market Capitalization (intraday) of $62.15M and CYRN stock one-year range is from $1.30 to $3.57 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/